Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
AssigneeAlexion Pharmaceuticals, Inc.
InventorsYi Wang, Louis Matis, Scott Rollins
Life of this patent
Estimating the term…
Abstract
The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN.
Claims5
A method for the treatment of pre-existing glomerulonephritis in a patient in need of such treatment comprising introducing an antibody specific to complement component C5 into the patient's bloodstream in an amount effective to substantially reduce the cell-lysing ability of complement present in the patient's blood.
Dependencies are inferred from the claim text.